|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.41 USD | +2.02% |
|
+13.57% | +13.46% |
| 07-30 | Teva CEO on Drug Pipeline, Direct Listing on NYSE | MT |
| 07-29 | Teva Pharmaceutical Industries Limited Reports Unaudited Consolidated Impairment Charges for the Second Quarter Ended June 30, 2026 | CI |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bullish | Neutral | Bullish |
| Resistance | 36.34 | 36.34 | 35.73 |
| Spread/Res. | -2.56% | -2.56% | -0.90% |
| Spread/Supp. | +9.90% | +24.90% | +39.35% |
| Support | 32.22 | 28.35 | 25.41 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- TEVA Stock
- Charts Teva Pharmaceutical Industries Limited
Select your edition
All financial news and data tailored to specific country editions
